JTCM

中医浆态

Journal of Traditional Chinese Medicine

Online Submissions: http://www.journaltcm.com info@journaltcm.com

J Tradit Chin Med 2016 October 15; 36(5): 564-577 ISSN 0255-2922 © 2016 JTCM. All rights reserved.

SYSTEMATIC REVIEW

Effects and safety of Sinomenine in treatment of rheumatoid arthritis contrast to methotrexate: a systematic review and Meta-analysis

Liu Weiwei, Qian Xian, Ji Wei, Lu Yan, Wei Gang, Wang Yue

Liu Weiwei, Internal Medicine of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210029, China

Qian Xian, Ji Wei, Lu Yan, Wei Gang, Wang Yue, Department of Rheumatism, the First Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210023, China

Supported by National Natural Science Foundation of China (Based on VIP to Investigate the Mechanism of Lung-Intestines Combined Therapeutic Method in Treating Sjogren's Syndrome No. 81473607); State Administration of Traditional Chinese Medicine Key Discipline Open Project (Bi-Syndrome of Traditional Chinese Medicine Science, No. BBXK2013101)

Correspondence to: Prof. Wang Yue, Department of Rheumatism, the First Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210023, China. wangyuephd@126.com

Telephone: +86-15150532007 **Accepted:** May 27, 2016

Abstract

OBJECTIVE: To systematically evaluate the curative clinical efficacy and safety of sinomenine (SIN) in treatment of rheumatoid arthritis (RA) in comparison to methotrexate (MTX).

METHODS: We searched the China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, China Science and Technology Journal Database, Wanfang Database, Pubmed and Cochrane Library electronically up to August 31, 2015, without language limitation. Only randomized controlled trials (RCTs) were included. Software Review Manager 5.3 was used for Meta-analysis.

RESULTS: A total of 16 eligible studies within 1500

RA patients were included. The meta-analysis indicated that on basis of MTX, SIN was more effective in total effective rate (P < 0.000 01). Besides, SIN alone versus MTX also showed advantages in RA therapy (P = 0.04) Taken together, adverse events occurred less frequently in combination of SIN and MTX than MTX alone (P < 0.0001), especially in digestive system (P < 0.00001), while occurred more in dermato mucosal system with SIN treatment versus MTX (P = 0.02), and were similar for both remedies in nervous system (P = 0.12) and hematological system (P = 0.25).

CONCLUTION: Compared to MTX, SIN had better clinical efficacy and relatively fewer adverse events in treatment of RA, especially when it was used together with MTX. Due to the poor methodological quality, well-designed, multiple-center RCTs are still required to further confirm the findings.

© 2016 JTCM. All rights reserved.

Key words: Sinomenine; Randomized controlled trials; Arthritis, rheumatoid; Methotrexate; Meta-analysis

INTRODUCTION

Rheumatoid arthritis (RA) is a progressive, destructive inflammatory disease afflicting around 0.5%-2% of the human population, especially females.¹ The domestic prevalence of RA is about 0.2% -0.4%.² RA is characterized by synovial inflammation leading to cartilage and bone damage that is largely irreversible.^{3,4} It usually starts as an insidious symmetrical polyarthritis, often with non-specific symptoms such as malaise and fatigue.⁵ 50%-90% patients with erosive disease first

develop their erosions > 2 years from disease onset.⁶ Although the exact cause of RA remains unknown, the "Bermuda triangle" of genetics, environment and autoimmunity is involved in the pathogenesis of RA.⁷ Methotrexate (MTX) is a disease modifying anti-rheumatic drug (DMARD) used as a first line agent for treating RA for its proven efficacy, relative safety, and cost-effectiveness.^{8,9} However, MTX is known to cause bone loss and promote osteoclast formation, which is far from ideal to prevent bone destruction in RA patients.^{10,11}

Sinomenine (SIN) is a pure alkaloid extracted from Chinese medicinal plant Qingfengteng (*Caulis Sinomenii*).¹² Qingfengteng (*Caulis Sinomenii*) is recorded initially in Ben Cao Tu Jing of the Song Dynasty, has functions such as dispelling the pathogen of wind and dampness, dredging the channels and collaterals and relieving pain.^{13,14} Studies have demonstrated that SIN possesses potent anti-inflammatory, analgesic, and immunoinhibitory pharmacological effects, which provide the basis for RA treatment.¹⁵

Natural plant products offer a promising resource for potential anti-arthritic agents, comprising one of the most popular complementary and alternative medicine (CAM) for inflammatory and immune disorders.^{3,16} Over the years, increasing proportion of patients with RA are resorting to CAM for their health needs. The prevalence of CAM usage by RA patients is anywhere between 28% to 90%.¹⁷ In parallel, increasingly studies have shown that SIN used alone or as adjuvant agent combined with MTX had synergistic effects in inhibiting RA response.^{18,19}

In this study, in comparison to MTX, we aimed to evaluate the clinical efficacy and safety of SIN in RA treatment.

METHODS

Literature retrieval and search strategies

Two reviewers searched the randomized controlled trials (RCTs) conducted for SIN in treating RA from database of China National Knowledge Infrastructure Database (CNKI), Chinese Biomedical Literature Database (CBM), China Science and Technology Journal Database (VIP), Wanfang Database, Pubmed and Cochrane Library. The search included articles published and updated up to August 31, 2015. Meanwhile, manual searches for gray literatures of conference compilations supplemented electronic searches were preformed, while no documents were provided. Full details on the search terms were described as follows: For Pubmed and Cochrane Library.

For Pubmed and Cochrane Library:

#1 Sinomenine [mh] OR Sinomenium [mh] OR Zheng Qing Feng Tong Ning [mh] OR Zhengqing Fengtongning tablets [mh]

#2 rheumatoid arthritis [mh] OR RA [mh]

#3 randomized controlled trials [pt] OR controlled clinical trial [pt] OR randomized [tiab] #1 AND #2 AND #3 For CNKI and other Chinese databases:

1# Qing Teng Jian [mh] OR Zheng Qing Feng Tong Ning [mh]

2# Lei Feng Shi Guan Jie Yan [mh] OR Joint Pain [mh] #1 AND #2

Inclusion criteria

(a) Types of studies. Trials must be a randomized, controlled design, regardless of blinding or allocation concealment. Quasi-RCTs were also taken into consideration. Restrictions on language, status or publication date were not set.

(b) Types of participants. According with specific clinical diagnosis of RA, any participants of selected cases were included whether mentioned patients were in active phase or not. The diagnostic criteria for RA in the trials accorded with the American Rheumatism Association 1987 revised criteria for the classification of RA.²⁰

(c) Types of interventions. Only trials of SIN preparations using alone or plus MTX versus MTX were considered Basic treatment may include non-steroidal anti-inflammatory drug (NSAIDs) such as meloxicam, but shouldn't include any other DMARDs or glucocorticoids.

(d) Types of outcome measures. The primary outcome was the clinical efficacy, the secondary outcomes included morning stiffness time, total clinical effective rate in 4 weeks treatment, swollen joint count (SJC), grip strength, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), blood platelet (PLT), disease activity score for rheumatoid arthritis in 28 joints (DAS28), health assessment questionnaire(HAQ) score, and other outcome (anti-CCP).

Exclusion criteria

Studies were not considered if they met any of the following criteria. (a) Unpublished or repeated literature; (b) non-RCTs, and clinical trials including experience summary, case report, traditional reviews and animal experiments; (c) studies not using SIN as the main means of intervention; diagnosis complicated with pregnancy, stroke, or other serious organic diseases such as heart, liver, kidney and hematopoietic dysfunction; (d) cases with patients of severe drug allergic medical history; (e) patients with other rheumatic diseases at the same time.

Data extraction and quality assessment

The titles and abstracts of potentially relevant references were identified through the literature search and reviewed independently by 2 reviewers (Liu Weiwei and Wei Gang) according to predefined criteria and the Cochrane risk of bias tool.²¹ Any inconsistencies were resolved by discussion (95% level of agreement) or further evaluated by consensus with another investigator (Wang Yue). We assessed the methodological quality of the included trials strictly according to the Cochrane risk of bias tool. For each item, the judgment was given as "high risk", "unclear risk", or "low risk".

Statistical analyses

Revman (version 5.3, the Nordic Cochrane Centre, Cochrane Collaboration, Copenhagen)²² and Stata 12.0 was used for data analysis. Outcomes were pooled using mean differences (MDs) for continuous variables, and pooled risk ratio (RR) was used for dichotomous variables, both with a 95% confidence interval (95% CI). Heterogeneity was tested using Chi-square (χ^2) test and I² statistic. When heterogeneity was defined as $P < 0.05, I^2 > 50\%$ among primary studies, it revealed significant heterogeneity, random effects model was to be used. Otherwise, if P > 0.05, $I^2 < 50\%$ fixed effects model was to be applied. To maximize the similarities among trials that would be combined, data was further stratified possibly into subgroups based on consideration of clinical factors, such as different types of interventions. Funnel plot analysis and Harbord's modified test²³ was done to determine publication bias. P < 0.05was considered statistically significant.

RESULTS

Characteristics of included studies

In this review, the initial search yielded 775 articles,

CNKI (n = 357), CBM (n = 44), VIP (n = 106), Wanfang Data (n = 227), Pubmed (n = 39) and Cochrane Library (n = 2), of which 431 were excluded owing to duplicated publication (n = 186) and irrelevant studies (n = 245). Following the evaluation of the full text, 328 articles not meeting the inclusion criteria were excluded, including non-RCTs (n = 14), combining other Chinese medicine or traditional Chinese in test group (n = 314). Finally, a total of 16 RCTs²⁴⁻³⁹ were available, all published in Chinese Journal Literature Databases from 2005 to 2015. The screening process is summarized in a flow diagram (Figure 1).

Literature analysis

The characteristics of the 16 RCTs^{24.39} are summarized in Table 1, containing a total of 1500 patients, each ranging from 40 to 186 patients. The experimental group consisted of 787 patients, while the control group contained 713 patients. All the studies included more females (67.1%) than males. The average age of the patients was approximately 44.1 years. The disease courses of RA were from 0.16 to 24 years. The dosage of SIN was administered orally from 60 mg qd to



Figure 1 Flow chart of literature search

CNKI: China National Knowledge Infrastructure Database; CBM: Chinese Biomedical Literature Database; VIP: Chinese Scientific Journals Database; RCTs: randomized controlled trials.

lable 1 Charad	teristics of 16 includ	ed studies	on SIN for KA							
Study	Diagnosis standard	Number (T/C)	Age (T/C)	Sex (M:F)	Course of disease (vears)	Intervention		Trial period (weeks)	Outcome measure	ADEs
Chen YL 2013 ²⁴	CDTESDSTCM	80/65	46.00±4.30	61:84	5.62±6.75	ZQFTN 60 mg q.d./b.i.d. p.o.	MTX 7.5-15 mg a.w. i.m.	12	$\mathbb{D}25$	Unclear
Ding H 2010 ²⁵	ACR-1987	31/31	16-63	18:44	0.16-17	ZQFTN 20-40 mg t.i.d. p.o.; MTX 7.5 ms a w n o	MTX 15 mg p.o.	12	Θ	Unclear
Gu F <i>et al</i> 2014 ²⁶	ACR/ FULAR-2010	45/45	40.40±10.11	23:67	7.90 ± 6.03	ZQFTN 40 mg t.i.d. p.o.; MTX 10 mg	MTX 10 mg q.w. p.o.	28	(236)	Yes
Huang ZS $et al 2010^{27}$	ACR-1987	30/30	42.50±7.50	22:38	3.45±3.40	Basic therapy+ZQFTN60 mg b.i.d. p.o. + MTX 7.5 mg q.w. p.o.	Basic therapy+MTX 15 mg q.w. p.o.	12	$\begin{array}{c} 1234\\ 56\end{array}$	Yes
Ji H <i>et al</i> 2006 ²⁸	ACR-1987	30/30	51.79±9.55	17:43	3.93±3.52	ZQFTN 20-40 mg t.i.d. p.o.; MTX 7.5 mg q.w. p.o.	MTX 15 mg q.w. p.o.	12	$\begin{array}{c} 1234\\ 56\\ \end{array}$	Yes
Liu W <i>et al</i> 2006^{29}	ACR-1987	60/60	42.75±7.65	19:101	3.15 ± 3.49	ZQFTN 60 mg q.d./b.i.d. p.o.	MTX 5-15 mg q.w. i.m.	12	$\begin{array}{c} 1234 \\ 5 \end{array}$	Yes
Ling Y et al 2014 ³⁰	ACR-1987	48/48	45.20±4.60	21:75	9.75±3.15	Basic therapy+ZQFTN 20-40 mg t.i.d. p.o.; MTX 7.5-15 mg q.w. p.o.	Basic therapy+ MTX7.5-15 mg q.w. p.o.	24	0 0 0 0 0 0 0	Yes
Lu Y et al 2011 ³¹	ACR-1987	40/40	46.76±13.40	19:61	3.50±3.54	Basic therapy+ZQFTN 120 mg b.i.d. p.o.; MTX 10 mg q.w. p.o.	Basic therapy+MTX 10 mg q.w. p.o.	12	0 0 0 0 0 0 0 0	Yes
Li YN <i>et al</i> 2008 ³²	ACR-1987	35/34	40.60±13.50	25:44	4.40±2.90	Basic threapy +ZQFTN 120 mg b.i.d.; MTX 10 mg	Basic therapy+MTX 10 mg q.w.	∞	$\begin{array}{c} 1234\\ 68\end{array}$	Yes
Sun SY et al 2006 ³³	ACR-1987	62/58	25.5-67.5	34:86	0.29-13.5	q.w. ZQFTN 120 mg q.d. p.o.; MTX 15 mg q.w. p.o.	MTX 15 mg q.w. p.o.	24	136	Yes
Sun SY 2008 ³⁴	ACR-1987	20/20	20.5-57	17:23	unclear	ZQFTN 60 mg q.d./b.i.d.	MTX 7.5-15 mg q.w. i.m.	12-24	125	Unclear
Wang WQ 2010 ³⁵	ACR-1987	120/66	13.5-71	66:120	0.75-4	Basic therapy+ZQFTN 120 mg b.i.d.; MTX 10 mg q.w.	Basic therapy+MTX 10 mg q.w.	24	$\begin{array}{c} 1230\\ 7900 \end{array}$	Yes
Xia YK et al 2012 ³⁶	ACR-1987; GCRNDTCM	52/52	37.50±6.90	21:83	4.60 ± 3.10	ZQFTN 60 mg t.i.d.; MTX 10 mg q.w. p.o.	MTX 10 mg q.w. p.o.	12	$\begin{array}{c} 123\\ 5600 \end{array}$	Yes
Zhu FX et al 2013^{37}	RA diagnostic criteria (unclear)	36/36	> 60	21:51	9.70±1.40	ZQFTN 60 mg b.i.d. p.o.; MTX 10 mg q.w. p.o.	MTX 10 mg q.w. p.o.	24	0 3 2 8 0 8	Yes
$ m Zhang JL 2015^{38}$	RA diagnostic criteria (unclear)	38/38	47.50±12.40	49:27	2.35±0.45	ZQFTN 120 mg b.i.d.; MTX 10 mg a.w. p.o.	MTX 10 mg q.w. p.o.	12	$\overset{}{0}$	Unclear
Zhang K et al 2005 ³⁹	ACR-1987; Grading standard	60/60	16-68	60:60	0.33-24	ZQFTN 120 mg b.i.d. p.o.	MTX 15 mg q.w. p.o.	12	$\begin{array}{c} 1234\\ 56\end{array}$	Yes
Notes: M: male day; tid: three t vised criteria; A	e; F: female; T: test; C imes a day; qw: once <i>i</i> .CR/EULAR-2010: th	2: control;] 1 week; Bas e Americar	RA: rheumatoid a iic therapy: take N 1 College of Rheun	rthritis; SIN SAIDs and/o matology/Eu	: sinomeine; ZQF 2r folic acid tablet 1ropean League Ag	"TN: Zhengqingfengtongning tablets; MTX: s orally; po: take orally; i.m: intramuscular inj şainst Rheumatoid collaborative initiative 201	methotrexate; ADEs: adverse jection; ARA-1987: the Amer 0 rheumatoid arthritis classif	e drug events; c rican Rheumati fication critera;	qd: every day; ism Associatio CDTESDST [,]	bid: twice n 1987 re- CM: crite-
ria of diagnosis	and therapeutic effect	of surgica	1 diseases and syn	dromes in Ti	raditional Chinese	Medicine; GCRNDTCM: Guidelines of clin	nical Research of New Drugs	of TCM. U cl	inical efficacy;	(2) morn-
ing stiffness tin joints; 10 healtl	ne;	nunt; 🕘 grī naire score.	ip strength; 近 ery	rthrocyte sed	Imentation rate; (0) C-reactive protein; (1) anti cyclic citrullinai	ted peptide; 🕲 blood platelei	st; (9) disease ac	tivity score fo	r KA in 28

Liu WW et al. / Systematic Review

120 mg bid over 8 weeks. For the experimental group, except 4 studies^{24,29,34,39} taking SIN alone, the rest of the studies^{25-28,30-33,35-38} were treated plus MTX versus MTX treatment alone, 5 trials^{27,30-32,35} adopted basic therapy, one³⁵ used folic acid to ameliorate side effects, 4 trials^{27,} ³⁰⁻³² used meloxicam during treatment, including one³⁰ also added folic acid. The dosages and treatment courses were not limited. 12 trials^{25,27-36,39} used the American Rheumatism Association 1987 revised criteria for the classification of RA (ARA-1987), including one ³⁹ added the double criteria of Grading standard.⁴⁰ One trial²⁶ used the American College of Rheumatology/European League Against Rheumatoid collaborative initiative 2010 RA classification criteria (ACR/EULAR-2010). For TCM diagnostic criteria, one trial²⁴ reported Wangbi in criteria of diagnosis and therapeutic effect of surgical diseases and syndromes in traditional Chinese medicine (CDTESDSTCM), one trial³⁶ applied with wind-dampness and blood-stagnant blocking collaterals syndrome according to Guidelines of Clinical Research of New Drugs of TCM (GCRNDTCM), 2 trials^{37,38} have not reported clear diagnostic criteria.

Methodological quality assessment

Study quality was evaluated by Cochrane risk of bias tool. All the eligible trials were RCTs, including one quasi-RCT.²⁵ None of the studies reported whether blinding was used, or described allocation concealment. Only 2 studies^{25,26} described specific methods of generating the random sequence, one²⁶ described as random digits table, and the other²⁵ represented as sequence of medical order, while the rest lacked a description. One study³¹ reported 1 drop-out during the duration of treatment. Interestingly, one study²⁶ described some clear secondary outcomes, while lacking data of clinical efficacy, we considered it may had selective reporting (Figures 2, 3). In addition, none of the trials reported a follow-up.

Clinical efficacy

Only 15 trials^{25,25,27-39} including 1410 patients took clinical efficacy as outcome measure. Meta-analysis showed little significant heterogeneity among the studies (P = 0.83 > 0.05, $I^2 = 0\% < 50\%$), RR = 1.13, 95% [1.08, 1.19]. Fixed effects model was taken into consideration. The overall effect tests (P < 0.000 01) suggested that test group combined with SIN had a more significant effective rate in treating RA than that of MTX (Figure 4).

Publication bias

The publication bias in 15 included articles²⁴⁻³⁹ was identified by funnel shape and Harbord's modified test. The reversed funnel-shape plot showed generally symmetrical (Figure 5), and the result of Harbord's modified test was not significant (t = 1.07, P = 0.302, Figure 6), indicating there might be no publication bias in those studies.

Subgroup analysis

Subgroup analysis was made on the clinical efficacy according to SIN alone and SIN plus MTX therapy both contrast to MTX group in RA therapy. 11 studies^{25-28,} ^{30-33,35-38} used SIN plus MTX as experimental group, while 4 studies^{24,29,34,39} took only SIN as test group. The heterogeneity (P = 0.45 > 0.05, $I^2 = 0\% < 50\%$) indicated that fixed effect model should be applied. The result revealed that groups with SIN alone also had higher effective rate than that of MTX (P = 0.04, Figure 7).

Sensitivity analysis

We removed the most³⁵ and the least³⁴ weighted of every subgroup and replaced fixed effects model to random effects model to confirm the stability of the 15 included studies²⁴⁻³⁹ on clinical efficacy. After removing the most weighted, the result was RR = 1.10, 95% *CI* (1.06, 1.15) (Figure 8), and the result of removing the least weighted was [RR = 1.11, 95% *CI* (1.07, 1.16), Figure 9]. Compared with the former results RR = 1.13, [95% *CI* (1.08, 1.19), Figure 4], there was no clear difference of RR values, which indicated low sensitivity and sound stability of the study.

Improvement of total clinical effective rate in 4 weeks treatment

Two trials^{33,36} were mentioned onset time in 4 weeks during trial period. There was significant heterogeneity (P < 0.00001, $I^2 = 95\% > 50\%$), random effect model was taken. The Meta-analysis showed that there weren't significant difference between groups of SIN plus MTX and MTX alone (P = 0.12, Figure 10).

Morning stiffness time

Among 12 studies^{24,26-30,32,34-39} there were 1162 patents



JTCM www. journaltcm. com



Figure 3 Risk of bias summary

Zhu FX et al 201337

with the description of morning stiffness time (min). High obvious heterogeneity was found (P < 0.000 01, $I^2 = 91\% > 25\%$), random effect model was applied. The result showed the test group with SIN could decrease morning stiffness time better than that of MTX (P < 0.000 01). Moreover, the subgroup analysis indicated that SIN alone also had better efficacy in decreasing morning stiffness time versus MTX (P = 0.008, Figure 11).

?

?

?

?

Swollen joint count (SJC)

Nine studies^{24,27-29,31,34,36,37,39} reported improvement in numbers of SJC. Heterogeneity test showed that studies had a considerable degree of heterogeneity (P =0.0009 < 0.05, $I^2 = 70\% > 50\%$), so random model

was chosen, there were significantly difference (P =0.008). In parallel, subgroup analysis showed that SIN alone had better efficacy in improving SJC (P = 0.02), while SIN plus MTX had no advantages (P = 0.23), both taken MTX as the contrast standard (Figure 12).

Grip strength

6 trials^{27-29,32,36,39} took grip strength (kpa) as the outcome measure. There was significant heterogeneity (P <0.000 01, $I^2 = 86\% > 50\%$), random effect model was taken. The Meta-analysis showed that test group combined with SIN was better than MTX alone in promoting grip strength (P = 0.03). The subgroup analysis indicated that there was significant difference in the group of SIN plus MTX (P = 0.04), while no difference in SIN alone (P = 0.71), both with the comparison of MTX therapy (Figure 13).

Erythrocyte sedimentation rate (ESR)

12 trials^{26-33,35-37,39} reported improvement in ESR. Heterogeneity test showed that the including studies had a considerable degree of heterogeneity (P < 0.000 01, $I^{2} = 76\% > 50\%$), so random model was chosen, the result showed that there were significantly difference $(P < 0.000 \ 01)$. The subgroup analysis showed that SIN alone had no advantages in decreasing ESR (P =0.41), while SIN plus MTX had better efficacy (P <0.000 01, Figure 14).

C-reactive protein (CRP)

Exact 11 studies^{26-28,30-33,35-37,39} referred to the improvement in decreasing CRP. Due to the heterogeneity (P < $0.000\ 01, I^2 = 88\% > 50\%$), we chose a random model. The result revealed that SIN combined with MTX had better efficacy in decreasing CRP than MTX alone (*P* < 0.0001, Figure 15).

Anti cyclic citrullinated peptide (anti-CCP)

Anti-CCP testing presents early in RA process and has proved to predict severe disease and irreversible damage.⁴¹ Unfortunately only was one trial³⁵ mentioned anti-CCP, we didn't take it in meta-analysis. The result in trial showed SIN plus MTX had better efficacy than MTX alone in decreasing anti-CCP (P < 0.05).

Blood platelet (PLT)

Two trials^{32,37} took PLT as outcome measure. Due to the heterogeneity (P = 0.26 > 0.05, $I^2 = 21\% < 50\%$), we choose a fixed model. The overall effect test (P <0.0001) indicated that the test group combined with SIN had a significantly effective rate in decreasing PLT than MTX alone (Figure 16).

Disease activity score for rheumatoid arthritis in 28 joints (DAS28)

There were 4 studies^{31,35,37,38} reported improvement in the DAS28.Heterogeneity test showed that the including studies had little heterogeneity (P = 0.85 > 0.05, $I^2 =$ 0% < 25%), so fixed effects model was chosen, the re-



Figure 4 Meta-analysis of the total clinical effective rate of sinomenine vs methotrexate in rheumatoid arthritis treatment



	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI	
16.1.1 SIN alone								
Chen YL 2013	66	80	46	65	9.2%	1.17 [0.97, 1.40]	-	
Liu W 2006	47	60	46	60	8.4%	1.02 [0.84, 1.24]	+	
Sun SY 2008	16	20	12	20	2.2%	1.33 [0.88, 2.03]		
Zhang K 2005	58	60	55	60	10.0%	1.05 [0.96, 1.15]	+	
Subtotal (95% CI)		220		205	29.8%	1.10 [1.00, 1.20]	•	
Total events	187		159					
Heterogeneity: Chi ² =	2.60, df	= 3 (P =	0.46); 1 ²	= 0%				
Test for overall effect:	Z = 2.06	(P = 0.)	04)					
16.1.2 SIN with comb	ination o	f MTX						
Ding H 2010	26	31	24	31	4 4%	1 08 [0 85 1 38]	+	
Huang 75 2010	27	30	26	30	4.7%	1.04 [0.86, 1.25]	+	
li H 2006	25	30	23	30	4.2%	1.09 [0.84, 1.40]	+	
Li YN 2008	35	35	31	34	5.8%	1.10 [0.97, 1.23]	-	
Ling Y 2014	45	48	38	48	6.9%	1.18 [1.01, 1.39]	+	
Lu Y 2011	29	40	25	40	4.6%	1.16 [0.85, 1.58]	+-	
Sun SY 2006	59	62	48	58	9.0%	1.15 [1.01, 1.31]	+	
Wang WO 2010	118	120	52	66	12.2%	1.25 [1.10, 1.42]		
Xia YK 2012	50	52	45	52	8.2%	1.11 [0.99, 1.25]	-	
Zhang JL 2015	33	38	27	38	4.9%	1.22 [0.96, 1.55]	-	
Zhu FX 2013	31	36	29	36	5.3%	1.07 [0.87, 1.32]	+	
Subtotal (95% CI)		522		463	70.2%	1.15 [1.09, 1.21]	4	
Total events	478		368					
Heterogeneity: Chi ² =	4.88, df	= 10 (P	= 0.90);	$^{2} = 0\%$				
Test for overall effect:	Z = 4.98	(P < 0.	00001)					
Total (95% CI)		742		668	100.0%	1.13 [1.08, 1.19]	•	
Total events	665		527					
Heterogeneity: Chi ² =	8.95, df	= 14 (P	= 0.83);	$^{2} = 0\%$				
Test for overall effect:	Z = 5.25	(P < 0.	00001)				U.UI U.I I 10	100
Test for subgroup diff	ferences:	$Chi^2 = 0$).56, df =	1 (P =	0.45), I ²	= 0%	ravours (experimental) ravours (control)	
Figure 7 Meta-analys	is for sub	group	s of sino	menin	e alone	versus Sinomening	plus methotrexate in clinical efficacy	

sult showed that SIN with MTX had better efficacy in decreasing DAS28 than MTX alone (P < 0.000 01, Figure 17).

The health assessment questionnaire (HAQ) score

Among 3 studies 30,35,36 there were 386 patents. Heterogeneity was shown in the studies (P < 0.000 01, I 2 =

	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
Chen YL 2013	66	80	46	65	5.4%	1.17 [0.97, 1.40]	÷
Ding H 2010	26	31	24	31	3.1%	1.08 [0.85, 1.38]	+
Huang ZS 2010	27	30	26	30	5.5%	1.04 [0.86, 1.25]	+
Ji H 2006	25	30	23	30	2.9%	1.09 [0.84, 1.40]	+
Li YN 2008	35	35	31	34	13.6%	1.10 [0.97, 1.23]	+
Ling Y 2014	45	48	38	48	7.0%	1.18 [1.01, 1.39]	
Liu W 2006	47	60	46	60	5.0%	1.02 [0.84, 1.24]	+
Lu Y 2011	29	40	25	40	2.0%	1.16 [0.85, 1.58]	+
Sun SY 2006	59	62	48	58	11.0%	1.15 [1.01, 1.31]	*
Sun SY 2008	16	20	12	20	1.1%	1.33 [0.88, 2.03]	
Xia YK 2012	50	52	45	52	12.9%	1.11 [0.99, 1.25]	-
Zhang JL 2015	33	38	27	38	3.3%	1.22 [0.96, 1.55]	
Zhang K 2005	58	60	55	60	23.1%	1.05 [0.96, 1.15]	+
Zhu FX 2013	31	36	29	36	4.3%	1.07 [0.87, 1.32]	Ť
Total (95% CI)		622		602	100.0%	1.10 [1.06, 1.15]	4
Total events	547		475				
Heterogeneity: Tau ² =	0.00; Chi	$^{2} = 5.5$	3, df = 1	3 (P = 0	0.96 ; $I^2 =$	0%	
Test for overall effect:	Z = 4.42	(P < 0.0)	0001)				Favours [experimental] Favours [control]

Figure 8 Sensitivity analysis of removing the most weighted

	Experim	ental	Contr	ol		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl	
Chen YL 2013	66	80	46	65	4.9%	1.17 [0.97, 1.40]	-	
Ding H 2010	26	31	24	31	2.8%	1.08 [0.85, 1.38]	+	
Huang ZS 2010	27	30	26	30	5.0%	1.04 [0.86, 1.25]	+	
Ji H 2006	25	30	23	30	2.6%	1.09 [0.84, 1.40]	+	
Li YN 2008	35	35	31	34	12.3%	1.10 [0.97, 1.23]	+	
Ling Y 2014	45	48	38	48	6.4%	1.18 [1.01, 1.39]	-	
Liu W 2006	47	60	46	60	4.5%	1.02 [0.84, 1.24]	+	
Lu Y 2011	29	40	25	40	1.8%	1.16 [0.85, 1.58]	+	
Sun SY 2006	59	62	48	58	9.9%	1.15 [1.01, 1.31]	*	
Wang WQ 2010	118	120	52	66	10.4%	1.25 [1.10, 1.42]	-	
Xia YK 2012	50	52	45	52	11.6%	1.11 [0.99, 1.25]	-	
Zhang JL 2015	33	38	27	38	3.0%	1.22 [0.96, 1.55]	-	
Zhang K 2005	58	60	55	60	21.0%	1.05 [0.96, 1.15]	+	
Zhu FX 2013	31	36	29	36	3.9%	1.07 [0.87, 1.32]	Ť	
Total (95% CI)		722		648	100.0%	1.11 [1.07, 1.16]	•	
Total events	649		515					
Heterogeneity: Tau ² =	= 0.00; Chi	$^{2} = 8.1$	2, $df = 1$	3 (P =	0.84); I ² =	= 0%		H
Test for overall effect	: Z = 5.17	(P < 0.	00001)				Favours [experimental] Favours [control])

Figure 9 Sensitivity analysis of removing the least weighted



Figure 10 Meta-analysis of total clinical effective rate in 4 weeks treatment in groups combined with sinomenine vs methotrexate

99% > 50%). The random effect model was used. The result showed that there was no obvious difference between the two remedies in improvement of HAQ score (P = 0.08, Figure 18).

Adverse events (ADEs)

12 studies^{26-33,35-37,39} including 1177 cases reported adverse events (ADEs) during RA treatment, mainly included digestive system including gastrointestinal upset (T/C: 23/46) and Serum alanine transaminase (ALT) raising (T/C: 6/26), hematological system including white blood cell (WBC) declining (T/C: 8/16), dermato mucosal system including skin rash(T/C: 26/8), and nervous system including dizziness (T/C: 2/6) (Table 2). The heterogeneity was no signifi-

cant (P = 0.5 > 0.05, $I^2 = 0\% < 25\%$), so the fixed model was applied. Taken together, ADEs occurred less frequently with the combination use of SIN than using MTX alone (P < 0.0001, Figure 19). Additionally, we made detailed analysis for ADEs of different systems, the results indicated that events occurred less frequently in the digestive system^{26-29,33,35-37,39} ($P < 0.000\ 01$, Figure 20) during the combination use of SIN treatment than during MTX therapy, but occurred more in the dermato mucosal system^{26-29,31,33,5-37,39} with SIN treatment (P = 0.02, Figure 21) than MTX therapy, while adverse events of the nervous system^{28,29,31,36} (P = 0.25, Figure 22) and hematological system^{26-29,31,36,37,39} (P = 0.12, Figure 23) were similar for both treatments.

	Expe	riment	al	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
18.1.1 SIN alone									
Chen YL 2013	41.07	30.12	80	79.15	46.28	65	8.5%	-38.08 [-51.12, -25.04]	
Liu W 2006	57	22.8	60	62.4	24	60	9.3%	-5.40 [-13.78, 2.98]	
Sun SY 2008	41.24	30.16	20	79.05	47.66	20	6.1%	-37.81 [-62.53, -13.09]	
Zhang K 2005 Subtotal (95% CI)	64.8	34.2	60	112.2	31.2	60	8.7%	-47.40 [-59.11, -35.69]	
Heterogeneity: Tau ² -	507 23	Chi ² -	30.03	df = 3	(P < 0	00001)	12 - 02%	51.04 [54.57, 0.52]	
Test for overall effect:	Z = 2.6	6 (P = 0	0.008)	, ui = 5	(1 < 0.	00001)	1 - 52%		
18.1.2 SIN combined	with M	гх							
Gu F 2014	47.44	35.84	45	65.33	54.14	45	7.3%	-17.89 [-36.86, 1.08]	
Huang ZS 2010	48	24	30	42	18	30	8.9%	6.00 [-4.74, 16.74]	<u>+</u>
Ji H 2006	41.5	31.87	30	47.01	30.05	30	8.0%	-5.51 [-21.18, 10.16]	
Li YN 2008	67.1	36.6	35	98.8	42.2	34	7.3%	-31.70 [-50.36, -13.04]	
Ling Y 2014	17.61	8.13	48	21.75	9.34	48	9.8%	-4.14 [-7.64, -0.64]	~~
Wang WQ 2010	61	17	120	98	35	66	9.2%	-37.00 [-45.98, -28.02]	
Xia YK 2012	55.8	42.5	52	85.9	53.1	52	7.4%	-30.10 [-48.59, -11.61]	
Zhu FX 2013 Subtotal (95% CI)	42	12	36 396	54	18	36 341	9.5% 67.4%	-12.00 [-19.07, -4.93] -15.70 [-26.21, -5.18]	
Heterogeneity: $Tau^2 =$	184.96	: Chi ² =	64.69	. df = 7	(P < 0.	00001)	$1^2 = 89\%$		-
Test for overall effect:	Z = 2.9	3 (P = 0	0.003)	, u. ,	(, , , , ,				
Total (95% CI)		- instantion	616			546	100.0%	-20.89 [-30.74, -11.04]	▲
Heterogeneity: Tau ² =	253.51	; Chi ² =	125.9	4, df =	11 (P <	0.0000	(1); $I^2 = 9$	1%	
Test for overall effect:	Z = 4.1	6 (P < 0	0.0001)					Favours [experimental] Favours [control]
Test for subgroup diff	erences	$Chi^2 =$	1.49,	df = 1 (P = 0.2	2), $I^2 =$	33.0%		
Figure 11 Meta-ana methotrexate	alysis c	of mor	ning	stiffne	ss tim	e with	n the su	bgroups of sinomen	ine alone and sinomenine plus methotrexate vs
	Exp	erimen	tal	c	ontrol			Mean Difference	Mean Difference
Study or Subaroup	Mean	SD	Total	Mean	SD	Total	Weight	IV. Random, 95% CI	IV. Random, 95% CI
20.1.1 SIN alone									
Chen YI 2013	7 43	5 26	80	10.62	4 13	65	8 5%	-3 19 [-4 72 -1 66]	
Lin W 2006	4 17	2 25	60	4 24	2 47	60	13.8%	-0.07 [-0.92 0.78]	
Sun SY 2008	7 42	5 25	20	10.73	4 27	20	3 4%	-3 31 [-6 28 -0 34]	
Zhang K 2005	3 29	0.89	60	4 08	0.76	60	18 1%	-0.79 [-1.09 -0.49]	
Subtotal (95% CI)	5.25	0.05	220	4.00	0.70	205	43.8%	-1.37 [-2.51, -0.23]	•
Heterogeneity: Tau ²	= 0.91;	$Chi^2 =$	15.00,	df = 3	(P = 0.	002); l ²	² = 80%		
Test for overall effect	t: Z = 2.	35 (P =	0.02)						
20.1.2 SIN combined	d with N	ИТХ							
Huang ZS 2010	4.2	1.8	30	4.1	2.2	30	12.3%	0.10 [-0.92, 1.12]	1 I
Ji H 2006	4.43	3.8	30	3.9	2.35	30	8.1%	0.53 [-1.07, 2.13]	ŕ
Lu Y 2011	4.41	2.65	40	5.62	2.77	40	10.9%	-1.21 [-2.40, -0.02]	1
Xia YK 2012	3.6	2.8	52	5.3	2.8	52	11.8%	-1.70 [-2.78, -0.62]	-
Zhu FX 2013 Subtotal (95% CI)	4.1	2.1	36 188	4.1	1.9	36 188	13.1% 56.2%	0.00 [-0.93, 0.93] -0.49 [-1.30, 0.31]	1
Heterogeneity: Tau ²	= 0.51:	Chi ² =	10.20	df = 4	(P = 0)	04): I ²	= 61%		

Total (95% Cl)408393100.0%-0.81[-1.42, -0.21]Heterogeneity: Tau² = 0.50; Chi² = 26.43, df = 8 (P = 0.0009); I² = 70%Test for overall effect: Z = 2.65 (P = 0.008)

Test for subgroup differences: $Chi^2 = 1.51$, df = 1 (P = 0.22), $I^2 = 33.8\%$

Figure 12 Meta-analysis of swollen joint count in subgroups of sinomenine alone and sinomenine plus methotrexate vs methotrexate

-100

-50

ò

Favours [experimental] Favours [control]

	Expe	rimen	tal	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
21.1.1 SIN alone							- 100 C - 100		
Liu W 2006	8.5	3.81	60	8.39	3.68	60	18.1%	0.11 [-1.23, 1.45]	
Zhang K 2005	14.28	3.06	60	14.11	2.26	60	19.2%	0.17 [-0.79, 1.13]	
Subtotal (95% CI)			120			120	37.4%	0.15 [-0.63, 0.93]	
Heterogeneity: Tau ² =	= 0.00; 0	$hi^2 =$	0.01, d	f = 1 (P	= 0.9	4); $ ^2 =$	0%		
Test for overall effect	: Z = 0.3	87 (P =	0.71)						
21.1.2 SIN combined	with M	тх							
Huang ZS 2010	9.07	2.8	30	8.93	2.93	30	17.8%	0.14 [-1.31, 1.59]	*
Ji H 2006	17.16	2.71	30	16.28	2.73	30	18.0%	0.88 [-0.50, 2.26]	
Li YN 2008	13.95	5.84	35	8.06	2.34	34	15.5%	5.89 [3.80, 7.98]	10
Xia YK 2012	25.6	9.6	52	19.7	7.5	52	11.3%	5.90 [2.59, 9.21]	77
Subtotal (95% CI)			147			146	62.6%	2.98 [0.16, 5.79]	•
Heterogeneity: Tau ² =	= 7.08; 0	$hi^2 =$	27.37,	df = 3 (P < 0.	00001)	$ ^2 = 89\%$	6	
Test for overall effect	: Z = 2.0)7 (P =	0.04)						
								a contract of the second	
Total (95% CI)			267			266	100.0%	1.82 [0.16, 3.47]	•
Heterogeneity: Tau ² =	= 3.47; 0	$chi^2 =$	35.29,	df = 5 (P < 0.	00001)	$ ^2 = 86\%$	6	
Test for overall effect	: Z = 2.1	15 (P =	0.03)						Favours [experimental] Favours [control]

Test for subgroup differences: $Chi^2 = 3.60$, df = 1 (P = 0.06), $I^2 = 72.3\%$

Figure 13 Meta-analysis of grip strength in subgroups of sinomenine alone and sinomenine plus methotrexate vs methotrexate

DISCUSSION

This review aimed to ascertain whether SIN therapy is

efficacious for RA, especially when combined with MTX treatment. It must be acknowledged, however, that the methodological quality of the studies was gen-

50

100

	Exp	eriment	al	c	ontrol	and be in the	Andre kan deren	Mean Difference	Mean D	ifference	
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Rando	m, 95% Cl	
22.1.1 SIN alone											
Liu W 2006	30.2	14.74	60	32.14	15.33	60	9.2%	-1.94 [-7.32, 3.44]	_	-	
Zhang K 2005	41.26	15.11	60	42.52	14.95	60	9.2%	-1.26 [-6.64, 4.12]	-	-	
Subtotal (95% CI)			120			120	18.5%	-1.60 [-5.40, 2.20]	•		
Heterogeneity: Tau ² =	0.00; 0	$hi^2 = 0$.03, df	= 1 (P =	= 0.86);	$l^2 = 0\%$	6				
Test for overall effect:	Z = 0.8	32 (P = 0)	0.41)								
22.1.2 SIN combined	with M	тх									
Gu F 2014	43.24	22.64	45	59.55	37.53	45	3.9%	-16.31 [-29.12, -3.50]			
Huang ZS 2010	28	11	30	31	10	30	9.3%	-3.00 [-8.32, 2.32]	_	+	
Ji H 2006	46.2	17.84	30	44.57	14.77	30	6.6%	1.63 [-6.66, 9.92]		-	
Li YN 2008	46.3	14.7	35	58.4	18.7	34	6.8%	-12.10 [-20.05, -4.15]			
Ling Y 2014	12.74	3.56	48	16.42	4.25	48	12.6%	-3.68 [-5.25, -2.11]			
Lu Y 2011	32.76	28.55	40	39.46	30.44	40	3.8%	-6.70 [-19.63, 6.23]		-	
Sun SY 2006	25.8	16.2	62	36.1	18.9	58	8.3%	-10.30 [-16.62, -3.98]			
Wang WQ 2010	28.35	10.56	120	40.56	9.78	66	11.6%	-12.21 [-15.23, -9.19]	~		
Xia YK 2012	20.3	12.6	52	31.2	14.2	52	9.5%	-10.90 [-16.06, -5.74]			
Zhu FX 2013	12.6	11.13	36	23.1	12.73	36	9.1%	-10.50 [-16.02, -4.98]			
Subtotal (95% CI)			498			439	81.5%	-8.12 [-11.58, -4.67]	•		
Heterogeneity: Tau ² =	19.96;	Chi ² =	41.57,	df = 9(P < 0.0	0001);	$ ^2 = 78\%$				
Test for overall effect:	Z = 4.6	51 (P < 0)	0.0000	1)							
Total (95% CI)			618			559	100.0%	-6.91 [-9.92, -3.90]	•		
Heterogeneity: $Tau^2 =$	18.03;	Chi ² =	46.65,	df = 11	(P < 0.	00001)	$ ^2 = 76\%$	6	+ <u>+ + - </u>		
Test for overall effect:	Z = 4.5	0 (P < 0	0.0000	1)					-100 -50	U 50	100
									ravours (experimental)	ravours [control]	

Test for subgroup differences: $Chi^2 = 6.19$, df = 1 (P = 0.01), I² = 83.8%

Figure 14 Meta-analysis of erythrocyte sedimentation rate in subgroups of sinomenine alone and sinomenine plus methotrexate *vs* methotrexate

	Exp	eriment	tal	c	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Gu F 2014	29.39	12.89	45	42.3	24.59	45	2.9%	-12.91 [-21.02, -4.80]	
Huang ZS 2010	6.5	2.3	30	7.1	2.6	30	13.3%	-0.60 [-1.84, 0.64]	
Ji H 2006	15.11	7.74	30	15.57	5.44	30	8.5%	-0.46 [-3.85, 2.93]	+
Li YN 2008	31.9	23.8	35	46.5	20.3	34	1.9%	-14.60 [-25.03, -4.17]	
Ling Y 2014	3.04	0.98	48	4.97	1.41	48	14.3%	-1.93 [-2.42, -1.44]	-
Lu Y 2011	7.12	8.24	40	9.65	8.96	40	7.8%	-2.53 [-6.30, 1.24]	~
Sun SY 2006	8.9	5.6	62	18.1	10.2	58	9.4%	-9.20 [-12.17, -6.23]	~
Wang WQ 2010	6.53	2.32	120	10.12	3.36	66	13.8%	-3.59 [-4.50, -2.68]	
Xia YK 2012	10.3	9.1	52	18.3	8.1	52	8.7%	-8.00 [-11.31, -4.69]	~
Zhang K 2005	17.38	13.56	60	19.52	14.31	60	5.7%	-2.14 [-7.13, 2.85]	-+
Zhu FX 2013	2.84	1.75	36	2.44	2.75	36	13.6%	0.40 [-0.66, 1.46]	
Total (95% CI)			558			499	100.0%	-3.37 [-4.90, -1.83]	•
Heterogeneity: $Tau^2 =$	= 4.22; 0	$chi^2 = 8$	4.76, d	f = 10(P < 0.0	0001):	$l^2 = 88\%$		
Test for overall effect	: Z = 4.3	30 (P <	0.0001						-100 -50 0 50 100
									Favours (experimental) Favours (control)

Figure 15 Meta-analysis of C-reactive protein in sinomenine plus methotrexate vs methotrexate



Figure 16 Meta-analysis of blood platelet in sinomenine plus methotrexate vs methotrexate

	Expe	rimen	tal	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Lu Y 2011	3.97	1.54	40	4.62	1.33	40	8.2%	-0.65 [-1.28, -0.02]	
Wang WQ 2010	4.5	1.2	120	5.2	1.7	66	15.3%	-0.70 [-1.16, -0.24]	
Zhang JL 2015	3.86	1.45	38	4.51	1.32	38	8.4%	-0.65 [-1.27, -0.03]	
Zhu FX 2013	2.7	0.6	36	3.2	0.3	36	68.1%	-0.50 [-0.72, -0.28]	
Total (95% CI) 234 180							100.0%	-0.56 [-0.74, -0.37]	
Heterogeneity: Chi ² =	0.80, d	f = 3 (P = 0.8	35); I ² =	: 0%				
Test for overall effect	Z = 6.0)2 (P <	0.000	01)					Favours [experimental] Favours [control]

Figure 17 Meta-analysis of disease activity score for rheumatoid arthritis in 28 joints in sinomenine plus methotrexate vs methotrexate

	Expe	rimer	Ital	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
Ling Y 2014	3.14	1.42	48	5.18	1.05	48	33.3%	-2.04 [-2.54, -1.54]	
Wang WQ 2010	1.1	0.7	120	1.2	0.5	66	33.8%	-0.10 [-0.27, 0.07]	+
Xia YK 2012	9.2	1.6	52	13.6	1.9	52	32.9%	-4.40 [-5.08, -3.72]	=
Total (95% CI)			220			166	100.0%	-2.16 [-4.54, 0.22]	•
Heterogeneity: Tau ² = Test for overall effect	= 4.37; 0 : Z = 1.7	Chi ² = 78 (P =	184.80 = 0.08)), df = 2	2 (P <	0.0000	1); $I^2 = 9$	9%	-100 -50 0 50 10 Favours (experimental) Favours (control)

Figure 18 Meta-analysis of health assessment questionnaire score in sinomenine plus methotrexate vs methotrexate

Table 2 Characteristics of 16	5 includ	ed stud	lies on adve	erse eve	nts for r	heumatoio	d arthrit	is				
C. 1			Treatmen	t group ((n)				Control	group (;	n)	
Study	DS	RS	DMS	HS	NS	A/T	DS	RS	DMS	HS	NS	A/C
Chen YL 2013 ²⁴						Un	clear					
Ding H 2010 ²⁵						Un	clear					
Gu F <i>et al</i> 2014 ²⁶	3	1	1	2	0	7/45	4	3	1	1	0	9/45
Huang ZS et al 2010 ²⁷	4	0	3	1	0	8/30	11	0	1	3	0	15/30
Ji H <i>et al</i> 2006 ²⁸	3	0	1	1	0	5/30	4	0	0	2	2	8/30
Liu W <i>et al</i> 2006 ²⁹	0	0	0	0	2	2/60	8	0	2	2	0	10/60
Ling Y et al 2014 ³⁰			Unclear			5/48			Unclear			13/48
Lu Y <i>et al</i> 2011 ³¹	0	0	1	0	0	1/40	1	0	0	1	1	2/40
Li YN <i>et al</i> 2008 ³²	0	0	2	0	0	2/35	0	0	0	0	0	0/34
Sun SY <i>et al</i> 2006 ³³	2	0	1	0	0	3/62	5	0	1	0	0	6/58
Sun SY 2008 ³⁴						Un	clear					
Wang WQ 2010 ³⁵	0	0	9	0	0	9/120	4	0	0	0	0	4/66
Xia YK <i>et al</i> 2012 ³⁶	12	0	5	3	0	20/52	20	0	0	4	3	27/52
Zhu FX et al 201337	3	0	1	0	0	4/36	4	0	1	1	0	6/36
Zhang JL 2015 ³⁸						Un	clear					
Zhang K et al 2005 ³⁹	2	0	2	1	0	5/60	11	0	2	2	0	15/60

Notes: DS: digestive system; RS: respiratory system; DMS: dermato mucosal system; HS: hematological system; NS: nervous system; A: number of adverse events; T: case number in treatment group; C: case number in control group.

	Experimental		Control		Risk Ratio		Risk Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
Gu F 2014	7	45	8	45	7.0%	0.88 [0.35, 2.21]	
Huang ZS 2010	8	30	14	30	12.2%	0.57 [0.28, 1.16]	
Ji H 2006	3	30	8	30	7.0%	0.38 [0.11, 1.28]	
Li YN 2008	2	35	0	34	0.4%	4.86 [0.24, 97.69]	
Ling Y 2014	5	48	13	48	11.3%	0.38 [0.15, 1.00]	
Liu W 2006	2	60	10	60	8.7%	0.20 [0.05, 0.87]	
Lu Y 2011	1	40	2	40	1.7%	0.50 [0.05, 5.30]	· · · · ·
Sun SY 2006	3	62	6	58	5.4%	0.47 [0.12, 1.78]	· · · ·
Wang WQ 2010	9	120	4	66	4.5%	1.24 [0.40, 3.86]	
Xia YK 2012	20	52	27	52	23.5%	0.74 [0.48, 1.14]	
Zhang K 2005	5	60	15	60	13.1%	0.33 [0.13, 0.86]	· · · · ·
Zhu FX 2013	4	36	6	36	5.2%	0.67 [0.21, 2.16]	
Total (95% CI)		618		559	100.0%	0.58 [0.45, 0.76]	•
Total events	69		113				
Heterogeneity: Chi ² =	10.30, df	= 11 (P = 0.50)				
Test for overall effect	: Z = 4.01	(P < 0.	0001)	0.01 0.1 1 10 100			
							ravours (experimental) ravours (control)

Figure 19 Meta-analysis of adverse events in the groups combined with sinomenine vs methotrexate

	Experimental		Experimental Control		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
Gu F 2014	3	45	4	45	5.6%	0.73 [0.15, 3.48]	
Huang ZS 2010	4	30	11	30	14.2%	0.27 [0.07, 0.96]	
Ji H 2006	3	30	4	30	5.4%	0.72 [0.15, 3.54]	
Liu W 2006	0	60	8	60	12.5%	0.05 [0.00, 0.91]	·
Lu Y 2011	0	40	1	40	2.2%	0.33 [0.01, 8.22]	· · · · · · · · · · · · · · · · · · ·
Sun SY 2006	2	62	5	58	7.4%	0.35 [0.07, 1.90]	
Wang WQ 2010	0	120	4	66	8.6%	0.06 [0.00, 1.09]	· · · ·
Xia YK 2012	12	52	20	52	22.9%	0.48 [0.20, 1.13]	
Zhang K 2005	2	60	11	60	15.8%	0.15 [0.03, 0.73]	
Zhu FX 2013	3	36	4	36	5.5%	0.73 [0.15, 3.51]	
Total (95% CI)		535		477	100.0%	0.34 [0.21, 0.53]	◆
Total events	29		72				
Heterogeneity: Chi ² =	7.59, df =	= 9 (P =	0.58); I ²				
Test for overall effect:	Z = 4.64	(P < 0.	00001)	Favours [experimental] Favours [control]			

Figure 20 Meta-analysis of digestive systematic adverse events in the groups combined with sinomenine vs methotrexate

	Experimental		Control			Odds Ratio	Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	CI M–H, Fixed, 95% CI		
Gu F 2014	1	45	1	45	9.1%	1.00 [0.06, 16.50]	0]		
Huang ZS 2010	3	30	1	30	8.4%	3.22 [0.32, 32.89]	9]		
Ji H 2006	1	30	0	30	4.4%	3.10 [0.12, 79.23]	3]	_	
Li YN 2008	2	35	0	34	4.4%	5.15 [0.24, 111.30]	0]	\rightarrow	
Liu W 2006	0	60	2	60	23.1%	0.19 [0.01, 4.11]	1] ←		
Lu Y 2011	1	40	0	40	4.5%	3.08 [0.12, 77.80]	0]		
Sun SY 2006	1	62	1	58	9.5%	0.93 [0.06, 15.29]	9]		
Wang WQ 2010	9	120	0	66	5.5%	11.33 [0.65, 197.87]	7]	\rightarrow	
Xia YK 2012	5	52	0	52	4.2%	12.16 [0.65, 225.77]	7]	\rightarrow	
Zhang K 2005	2	60	2	60	18.0%	1.00 [0.14, 7.34]	4]		
Zhu FX 2013	1	36	1	36	9.0%	1.00 [0.06, 16.63]	3]		
Total (95% CI)		570		511	100.0%	2.40 [1.17, 4.89]	9]		
Total events	26		8						
Heterogeneity: Chi ² =	7.19, df =	= 10 (P	= 0.71);	$1^2 = 0\%$				100	
Test for overall effect:	Z = 2.40	(P = 0.0)	02)				Favours [experimental] Favours [control]	100	

Figure 21 Meta-analysis of dermato mucosal systematic adverse events in the groups combined with sinomenine vs methotrexate

	Experimental		Control		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Ji H 2006	0	30	2	30	31.2%	0.19 [0.01, 4.06]	·
Liu W 2006	2	60	0	60	6.1%	5.17 [0.24, 110.01]	
Lu Y 2011	0	40	1	40	18.8%	0.33 [0.01, 8.22]	
Xia YK 2012	0	52	3	52	44.0%	0.13 [0.01, 2.67]	• •
Total (95% CI)		182		182	100.0%	0.49 [0.15, 1.65]	
Total events	2		6				
Heterogeneity: Chi ² =	3.44, df =	= 3 (P =	0.33); I ²	= 13%			
Test for overall effect	z = 1.15	(P=0.	25)				Favours [experimental] Favours [control]

Figure 22 Meta-analysis of nervous systematic adverse events in the groups combined with sinomenine vs methotrexate

	Experimental		Contr	ol	Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M–H, Fixed, 95% Cl
Gu F 2014	2	45	1	45	5.6%	2.05 [0.18, 23.41]	· · · · · · · · · · · · · · · · · · ·
Huang ZS 2010	1	30	3	30	17.1%	0.31 [0.03, 3.17]	
Ji H 2006	1	30	2	30	11.4%	0.48 [0.04, 5.63]	· · · · ·
Liu W 2006	0	60	2	60	14.6%	0.19 [0.01, 4.11]	• • •
Lu Y 2011	0	40	1	40	8.7%	0.33 [0.01, 8.22]	· · · ·
Xia YK 2012	3	52	4	52	22.2%	0.73 [0.16, 3.46]	
Zhang K 2005	1	60	2	60	11.6%	0.49 [0.04, 5.57]	
Zhu FX 2013	0	36	1	36	8.7%	0.32 [0.01, 8.23]	· · · ·
Total (95% CI)		353		353	100.0%	0.53 [0.24, 1.18]	-
Total events	8		16				
Heterogeneity: Chi ² =	2.16, df =	= 7 (P =	0.95); I ²				
Test for overall effect:	Z = 1.55	(P = 0.	12)				Favours [experimental] Favours [control]

Figure 23 Meta-analysis of hematological systematic adverse events in the groups combined with sinomenine vs methotrexate

erally not high. Firstly, the cases in our included articles were from 40 to 186, which meant there were no large-scale RCTs, the current evidence was insufficient to make a routine recommendation of SIN for RA treatment. Besides, we thoroughly searched the English database, while no eligible studies were found.

Secondly, among the 16 eligible trials²⁴⁻³⁹, only 4 trials^{24, ^{29,34,39} applied an A versus B design (totally different make-up between the two groups), rest of the trials used an A + B versus B design where patients are randomized to receive a experimental treatment plus the control treatment (Treatment Group) versus the control treatment (Control Group). This kind of design tend to generate false positive results. Thus, stakeholders should take critical thinking about the positive conclusions.}

Thirdly, the duration of therapy in our included trials was indeed too short to achieve conclusive results during the chronic course of RA. Furthermore, none was mentioned a follow-up period. The outcomes were only assessed at the end of the treatment (ranging from 8-24 weeks). Some long-term ADEs such as liver and kidney functional damage would not be properly assessed. Additionally, it is worth noting that all the trials mentioned the number of ADEs, without distinguishing whether its stands for patients' number of ADEs or the number of ADE phenomenon itself, which may lead to repeated counting and the final heterogeneity in our Meta-analysis.

In conclusion, Meta-analysis can save cost and time disposing the data of multiple independent trials to increase sample size and to sharpen test performance. Besides, it can provide evidence-based medical evidence for clinicians in the areas of clinical practice.

This Meta-analysis from 15 aspects mentioned above revealed that SIN therapy, especially combined with MTX for RA had better clinical efficacy with less adverse events than MTX therapy alone. In conclusion, SIN may be a valuable way to treat RA in clinical practice, and the combination of SIN and MTX should be taken more seriously clinically, although current evidence needs to be further verified by more high-quality trials.

ACKNOWLEDGEMENTS

We would like to thank Dr. Chen Shi of Nanjing University of Traditional Chinese Medicine for his perfective work on STATA analysis for this article.

REFERENCES

- 1 **Korczowska L**. Rheumatoid arthritis susceptibility genes: An overview. World J Orthop 2014; 5(4): 544-549.
- 2 The Chinese Medical Association of Rheumatology. Guidelines for diagnosis and treatment of rheumatoid arthritis. Xian Dai Shi Yong Yi Xue 2004; 16(3): 184-188.
- 3 **Venkatesha SH**, Rajaiah R, Berman BM, Moudgil KD. Immunomodulation of autoimmune arthritis by Herbal CAM. Evid Based Complement Alternat Med 2011; 26 (5): 1-13.
- 4 Giovagnoni A, Valeri G, Burroni E, Amici F. Rheumatoid arthritis: follow-up and response to treatment. Eur J Radiol 1998; 27 Suppl 1(2): S25-S30.
- 5 **Takeuchi T.** Biological agents for therapy of rheumatoid arthritis: overview. Nihon Rinsho 2005; 63 Suppl 1(2): S513-S516.
- 6 **Bukhari M**, Hanison B, Lunt M, et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum 2001; 44(6): 1248-1253.
- 7 Kurkó J, Besenyei T, Laki J, et al. Genetics of rheumatoid arthritis - a comprehensive review. Clin Rev Allergy Immunol 2013; 45(2): 170-179.
- 8 Ortiz Z, Shea B, Suarez AM, Mother D, Wells G, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. J Evid Based Med 2001; 5(6): 1049-1060.
- 9 Jay R. Methotrexate revisited: considerations for subcutaneous administration in RA. Clinical Rheumatology 2014; 34(2): 201-205.
- 10 Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Chihara K. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res 1997; 12(5): 734-741.
- 11 King TJ, Georgiou KR, Cool JC, et al. Methotrexate chemotherapy promotes osteoclast formation in the long bone of rats via increased pro-inflammatory cytokines and enhanced NF-κB activation. Am J Pathol 2012; 181(1): 121-129.
- 12 Yu Q, Zhu S, Zhou R, et al. Effects of sinomenine on the expression of microRNA-155 in 2,4,6-trinitrobenzenesulfonic acid-induced colitis in mice. PLoSOne 2013; 8(9): 737-757.
- 13 Su Y. Research of Ben Cao Tu Jing. Beijing: People's Medi-

cal Publishing House, 2011: 8-9.

- 14 Xie M, He YS, Fan QL. Pharmacology of traditional Chinese medical formulae. 16th ed. Beijing. People's Medical Publishing House, 2010: 398.
- 15 Sun J, Shi JM, Zhang TH, et al. Impact of release characteristics of sinomenine hydrochloride dosage forms on its pharmacokinetics in beagle dogs. World J Gastroenterol 2005; 11(29): 4547-4551.
- 16 Nanjundaiah SM, Astry B, Moudgil KD. Mediators of inflammation-induced bone damage in arthritis and their control by herbal products. Evid Based Complement Alternat Med 2013; 25(1): 57-65.
- 17 **Effhimiou P**, Kukar M. Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities. Rheumatol Int 2010; 30(5): 571-586.
- 18 Zhang YL, Ouyang GL, Xiao LB. Research advances of mechanism of sinomenine in treating rheumatoid arthritis. Zhong Xi Yi Jie He Xue Bao 2009; 7(8): 775-778.
- 19 Sun Y, Ding CZ, Yao Y. Effects of sinomenine and methotrexate on fibroblast-like synoviocytes in rheumatoid arthritis. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2012; 32 (8): 1107-1111.
- 20 Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31(3): 315-324.
- 21 Higgins JPT, Altman DG, Sterne JAC (editors) (2011). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
- Review Manager (RevMan) [Computer program]. Version5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- 23 **Harbord RM**, Egger M, Sterne JAC. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Stat Med, 2006, 25(25): 3443-3457.
- 24 **Chen YL**. The clinical efficacy analysis of 80 cases of rheumatoid arthritis treated by Zheng Qing Feng Tong Ning tablet. Zhong Guo Wei Sheng Chan Ye 2013; 6(1): 83.
- 25 **Ding H**. 60 cases of Clinical observation of rheumatoid arthritis. Yi Hu Lun Tan 2010; 7(13): 218.
- 26 Gu F, Sun Y, Chen SW, Wang P, Ding CZ, Sun LY. Clinical study of sinomenine in combination with methotrexate for the treatment of active rheumatoid arthritis. Shanghai Zhong Yi Yao Za Zhi 2014; 48(6): 58-60.
- 27 **Huang ZS**, Wang N. Clinical observation on the treatment of rheumatoid arthritis with Zhengqing Fengtongning sustained release tablets. Hebei Yi Yao 2010; 32(1): 59-60.
- 28 Ji H, Zhu ZH. Small dose of Zhengqing Fengtongning combined with methotrexate in the treatment of rheumatoid arthritis: 30 cases. Yi Yao Dao Bao 2006; 25(1): 37-38.
- 29 Liu W, Liu XY, Liu B. Clinical observation on treatment of rheumatoid arthritis with Zhengqing fengtongning Retard Tablets: a report of 60 cases. Zhong Xi Yi Jie He Xue

Bao 2006; 4(2): 201-202.

- 30 **Ling Y**, Wang NS, Feng H, Xie J, He DY. Clinical study of sinomenine combined with methotrexate on the repair of bone destruction in rheumatoid arthritis. Shi Jie Lin Chuang Yao Wu 2014; 35(5): 279-282.
- 31 **Lu Y**, Su JM. Observation on the efficacy of the treatment of rheumatoid arthritis with the combination of Zhengqing Fengtongning and methotrexate in the treatment of rheumatoid arthritis. Liaoning Zhong Yi Za Zhi 2011; 38 (10): 2019-2020.
- 32 Li YN, Feng XG, Zhang SL, Li CM. Effects of sinomenine combined with methotrexate on rheumatoid arthritis. Shi Yong Yao Wu Yu Lin Chuang 2008; 11(5): 285-287.
- 33 Sun SY, Lan HM. Summarization on the treatment of 62 cases of Rheumatoid Arthritis with Zhengqin Fengtongnin tablets and methopterin. Zhong Yi Yao Dao Bao 2006; 12(1): 40-41.
- 34 **Sun SY**. Clinical effect of the treatment of rheumatoid arthritis with Zhengqing Fengtongning tablets. Zhong Wai Yi Liao 2008; 27(30): 105.
- 35 **Wang WQ**. 120 cases of rheumatoid arthritis treated with the combination of methotrexate and Zhengqing Fengtongning. Zhejiang Shi Yong Yi Xue 2010; 15(4): 280-281.

- 36 Xia YK, Xu SH, Hu YH, Wang L, Chen Z, Liu YF. Observation on the efficacy of methotrexate combined with Zhengqing Fengtongning for the treatment of rheumatoid arthritis in active stage. Zhong Xi Yi Jie He Yan Jiu 2012; 4 (5): 225-228.
- 37 **Zhu FX**, Zhou RH, Shi YH, Mo HY, Li BZ, Li LM. Clinical study of Zhengqing Fengtongning combined with methotrexate in treatment of elderly rheumatoid arthritis. Xian Dai Yu Fang Yi Xue 2013; 40(15): 2944-2949.
- 38 **Zhang JL**. Observation on the efficacy of the treatment of rheumatoid arthritis with the combination of Zhengqing Fengtongning and methotrexate in the treatment of rheumatoid arthritis. Zhong Guo Xian Dai Yao Wu Ying Yong 2015; 9(7): 110-111.
- 39 Zhang K, Fu ZL, Wang K, Liu XM. Effect of Zhengqing Fengtongning on the expression of RANTES in rheumatoid arthritis. Lin Chuang Yi Yao Shi Yan Za Zhi 2005; 14 (12): 893-895.
- 40 **Yao FX.** Modern rheumatology. Beijing: People's Medical Publishing House, 1995: 200.
- 41 **Nobuhide H**, Shunichi K. Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis. Rinsho Byori 2010; 58(5): 466-479.